Video Shorts

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Majority of Myeloma patients are > 65 years of age at diagnosis & that makes Geriatric Assessment a critical for these patients. Historically we have focused on Cytogenetic & Biochemical evaluation but not so much on geriatric assessment.

Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.

Cardiac care is not fully integrated in cancer care plans in most canters across the world. This is an important next step in evolution of cancer care.

Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.